Sign In
Buy CNS
$70.20
-1.00 (-1.40%)
At Close: Jun 03, 2026
NorthC Data Centers Doubles Down on Corero Network Security for European Expansion
07:00am, Thursday, 10'th Apr 2025
Three-year renewal deepens partnership, powering protection, performance, and proven value for customers at scale. LONDON , April 10, 2025 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (O
Cohen & Steers, Inc. to Release First Quarter 2025 Results on April 16, 2025
05:30pm, Wednesday, 09'th Apr 2025
NEW YORK , April 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release first quarter 2025 results after the market closes on Wednesday, April 16, 2025. The ear
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for March 2025
05:45pm, Tuesday, 08'th Apr 2025
NEW YORK , April 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $87.6 billion as of March 31, 2025, a decrease of $979 million from ass
Corero Network Security Secures Major 400G TechEnabler Deal, Marks Fourth Brazil Win in Four Months
07:00am, Thursday, 03'rd Apr 2025
LONDON , April 3, 2025 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced a new strategic partnership
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
08:05am, Tuesday, 01'st Apr 2025
Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical eff
Juniper Networks Expands Partnership with Corero Network Security to Deliver Industry-Leading DDoS Protection Across Any Network
07:00am, Tuesday, 01'st Apr 2025
Juniper can now deliver Corero's full DDoS protection suite, enabling stronger security and resilience across mixed network environments. LONDON , April 1, 2025 /PRNewswire/ -- Corero Network Securit
Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
05:52pm, Monday, 31'st Mar 2025
NEW YORK , March 31, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of
Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
05:49pm, Monday, 31'st Mar 2025
NEW YORK , March 31, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources o
Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
05:46pm, Monday, 31'st Mar 2025
NEW YORK , March 31, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the di
Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
05:28pm, Monday, 31'st Mar 2025
NEW YORK , March 31, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of t
Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
05:21pm, Monday, 31'st Mar 2025
NEW YORK , March 31, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) (the "Fund") with information regarding the s
Cohen & Steers Closed-End Funds Declare Distributions for April, May and June 2025
04:05pm, Thursday, 27'th Mar 2025
NEW YORK , March 27, 2025 /PRNewswire/ -- The Boards of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for April, May and June 2025, as summarized in the ch
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
12:05pm, Tuesday, 25'th Mar 2025
CNS Pharmaceuticals, Inc. CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
08:00am, Tuesday, 25'th Mar 2025
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety pr
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication
